• Revenue grew 8.3% to $3.6B+
• EBITDA up 3% to $95.2M
• Net Profit After Tax excluding PPA up 9.5% to $31.2M

ParagonCare, a leading healthcare distributor in the APAC region, reported strong financial results for FY25. Revenue grew 8.3% to over $3.6 billion, driven by a 11.6% increase in total pharmacy sales to $2.8 billion, the integration of Oborne's complementary medicines business unit, and continued expansion of the medical consumables range. Medical Technology sales grew 1% to $298 million, with expansion in the Surgical Robotics and Aesthetics portfolios offsetting softness in capital, service and vision businesses. Contract Logistics sales grew 25% to $336 million, benefiting from a large-scale contract with Owens and Minor. Clinical Manufacturing sales increased 9% to $25 million, with the signing of the first contract manufacturing agreement. EBITDA increased 3% to $95.2 million, while Net Profit After Tax excluding PPA rose 9.5% to $31.2 million. The company made progress on its strategic initiatives, including the integration of Oborne, Design For Vision, REM Australia, WBM, SMS and parts of Surgical Specialties onto the JDE ERP system, and the expansion of its Aesthetics and Dental business units across the APAC region.